Now Playing
|Videos|August 30, 2022
Initial Impressions and Analysis of an mCSPC Patient Case
Author(s)Marc Matrana, MD
Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.
Advertisement
Episodes in this series
Advertisement
Related to this article
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
The FDA recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
The NCCN Guidelines indicate rusfertide for patients regardless of risk status for patients who are intolerant to phlebotomy or receive frequent phlebotomy.
Community oncology practices rapidly adopt bispecific therapy, but reimbursement gaps, intensive monitoring demands, and limited hospital coordination hinder safe, scalable in-office programs.
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Evaluating Platelet- vs Immune-Directed Therapies in Immune Thrombocytopenia
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Survey Reports Widespread Adoption of Bispecifics in Community Oncology
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5